



Curriculum Vitae

Personal information Honar Cherif

Work experience

1. Employer: Lidköping Hospital
 - Start date: 061995
 - End date: 061997
 - Position: Rotation and internship
 - Activities:
 - Country: Sweden
2. Employer: Lidköping and Sahlgrenska Hospital
 - Start date: 061997
 - End date: 062002
 - Position: Senior house officer, Fellowship medicine and Hematology
 - Activities:
 - Country: Sweden
3. Employer: Karolinska Univ Hospital
 - Start date: 062002
 - End date: 062006
 - Position: Specialist in Hematology
 - Activities:
 - Country: Sweden
4. Employer: Karolinska Univ Hospital
 - Start date: 062006
 - End date: 062008
 - Position: Consultant Hematologist Part_time
 - Activities:
 - Country: Sweden
5. Employer: Wyeth Pharmaceuticals
 - Start date: 062007
 - End date: 032009
 - Position: Medical Advisor
 - Activities: Worked same period at Karolinska Univ Hospital part_time
 - Country: Sweden
6. Employer: Senior Consultant Hematologist
 - Start date: 042009
 - End date:
 - Position: Uppsala University Hospital
 - Activities:
 - Country: Sweden
7. Employer: Uppsala University Hospital
 - Start date: 062013
 - End date: 032020
 - Position: Head of Department of Hematology
 - Activities:
 - Country: Sweden
8. Employer: Uppsala University Hospital
 - Start date: 032020
 - End date: 122020
 - Position: Acting Medical Director of Hematology and Oncology
 - Activities:
 - Country: Sweden

Education and training

1. Subject: Baghdad University
 - Start date: 061986
 - End date: 081991
 - Qualification: MB CHB
 - Organisation:
 - Country:
2. Subject: Sahlgrenska Univ Hospital and Lidköping Hospital
 - Start date: 061997
 - End date: 062002
 - Qualification: Swedish Board in Hematology and Internal Medicine
 - Organisation:
 - Country: Sweden
3. Subject: Karolinska Institute
 - Start date: 062002
 - End date: 112005
 - Qualification: PhD in Hematology
 - Organisation:
 - Country: Sweden
4. Subject: Uppsala University
 - Start date: 062015

- End date:
 - Qualification: Associate Professor in Hematology
 - Organisation:
 - Country: Sweden
5. Subject: Qatar University
- Start date: 062021
 - End date:
 - Qualification: Honorary Professor of Hematology
 - Organisation:
 - Country: Qatar

Additional information

Publications

1_ Cherif H, Kronvall G, Björkholm M, Kalin M. Bacteraemia in hospitalised patients with malignant blood disorders: a retrospective study of causative agents and their resistance profiles during a 14_year period without antibacterial prophylaxis. *Hematol J* 2003; 4:420_6. 2_ Cherif H, Björkholm M, Engervall P, Johansson P, Ljungman P, Hast R, Kalin M. A prospective, randomized study comparing cefepime and imipenem_cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. *Scand J Infect Dis* 2004; 36:593_600. 3_ Cherif H, Landgren O, Konradsen HB, Kalin M, Björkholm M. Poor antibody response to pneumococcal polysaccharide vaccination suggests increased susceptibility to pneumococcal infection in splenectomized patients with hematological diseases. *Vaccine* 2006 Jan 9;24(1):75_81. 4_ Chryssanthou E, Cherif H, Petrini B, Kalin M, Björkholm M. Surveillance of triazole susceptibility of colonizing yeasts in patients with haematological malignancies. *Scand J Infect Dis* 2004; 36:855_9 5_ Cherif H, Khoshkar J, Stenke L, Hellström PM. *Helicobacter pylori* in a cohort of 76 patients with immune thrombocytopenic purpura. No increased prevalence or apparent platelet response to eradication therapy. *Haema*. 2005; 8(1):94_98. 6_ Cherif H, Johansson E, Björkholm M, Kalin M. The feasibility of early hospital discharge with oral antimicrobial therapy in low risk patients with febrile neutropenia following chemotherapy for hematological malignancies: A prospective validation and clinical application of the risk_index of the Multinational Association of Supportive Care in Cancer. *Haematologica*; 2006 Feb; 91(2):215_22. 7_ Cherif H, Kalin M, Björkholm M. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? *Eur J Haematol*. 2006; 77:288_292. 8_ Cherif H, Martling C_R, Hansen J, Kalin M, and Björkholm M. Predictors of short and long_term outcome in patients with haematological disorders admitted to the intensive care unit for a life_threatening complication. *Journal of Supportive Care in Cancer*. 2007. 9_ Kalin M, Kristinsson SY, Cherif H, Lebbad M, Björkholm M. Fatal pneumocystis jiroveci pneumonia in ABVD_treated Hodgkin lymphoma patients. *Ann Hematol*. 2010 May;89(5):523_5. 10_ Cherif H, Axedorph U, Kalin M, Björkholm M. Clinical experience of granulocyte transfusion in the management of neutropenic patients with haematological malignancies and severe infection. *Scand J Infect Dis*. 2013 Feb;45(2):112_6. 11_ Lehmann S, Bykov VJ, Ali D, Andrén O, Cherif H, Tidefelt U, et al. Targeting p53 in Vivo: A First_in_Human Study With p53_Targeting Compound APR_246 in Refractory Hematologic Malignancies and Prostate Cancer. *J Clin Oncol*. 2012 Oct 10;30(29):3633_9. 12_ Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG. Low all_cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single_center study. *Eur J Haematol*. 2012 May;88(5):422_30. 13_ Johan Blomgren, Gunnar Dahlen, Charlotta Edlund, Honar Cherif, Bengt Götrick, et al (as an expert group). Indications for antibiotic prophylaxis in dental care, Recommendations from the Swedish Medical Products Agency. *Info Swe Med Prod Agency*, Vol 23, nr 5, October 2012. 14_ Cherif H, Höglund M, Pauksens K, Adjuvanted Influenza A (H1N1) 2009 Vaccine in Patients With Hematological Diseases: Good Safety and Immunogenicity Even in Chemotherapy_Treated Patients. *Eur J Haematol*. 2013 Feb 27. 15_ Svensson T, Höglund M, Cherif H, Clinical significance of serum immunoglobulin G subclass deficiency in patients with chronic lymphocytic leukemia. *Scand J Infect Dis*. 2013 Feb 21. 16_ Svensson T, Cherif H, Höglund M, Answer to "Letter to the Editor. *Scand J Infect Dis*. 2013 Sep;45(9):730. 17_ Cherif H, Karlsson T, Combination treatment with an erythropoiesis_stimulating agent and intravenous iron alleviates anaemia in patients with hereditary haemorrhagic telangiectasia. *Ups J Med Sci*. 2014 Nov;119(4):350. 18_ Svensson T, Chowdhury O, Garelius H, Lorenz F, Saft L, Jacobsen SE, Hellström_Lindberg E, Cherif H. A pilot phase I dose finding safety study of the thrombopoietin_receptor agonist, eltrombopag, in patients with myelodysplastic syndrome treated with azacitidine. *Eur J Haematol*. 2014 Nov;93(5). 19_ Deneberg S, Cherif H, Lazarevic V, Andersson PO, Juliusson G, Lehmann S1, An open_label phase I dose_finding study of APR_246 in hematological malignancies. *Blood Cancer J*. 2016 Jul 15;6(7):e447. 20_ Karlsson T, Cherif H. Effect of Intravenous Iron Supplementation on Iron Stores in Non_Anemic Iron_Deficient Patients with Hereditary Hemorrhagic Telangiectasia. *Hematol Rep*. 2016 Mar 21;8(1):6348. 21_ Ekstrand C, Linder M, Cherif H, Kieler H, Bahmanyar S. Increased susceptibility to infections before the diagnosis of immune thrombocytopenia. *J Thromb Haemost*. 2016 Apr;14(4):807_14. 22_ Svensson T, Lundström KL, Höglund M, Cherif H. Utility of bronchoalveolar lavage in diagnosing respiratory tract infections in patients with hematological malignancies: are invasive diagnostics still needed? *Ups J Med Sci*. 2017 Mar;122 23_ Löfling L, Linder M, Ekstrand C, Cherif H, Kieler H, Bahmanyar S. Pharmacological agents preceding a diagnosis of immune thrombocytopenia in adult patients developing the chronic form: A Swedish national register study. *Thromb Res*. 2017 Dec;160:27_31. 24_ Cherif H, Lubinow N. Patient was wrongly diagnosed and repeatedly treated for immune thrombocytopenia for 50 years; *Lakartidningen*. 2018 Mar 13;115. 25_ Berlin G, Cherif H, Knutson F, Mattsson J, Axedorph Nygell U. Granulocyte transfusion; when and how should it be used? *Lakertidningen* Mar 20. 26_ Svensson T, Kättström M, Cherif H, Kimby E. Pneumococcal conjugate vaccine triggers a better immune response than pneumococcal polysaccharide vaccine in patients with chronic lymphocytic leukemia A randomized study by the Swedish CLL group. *Vaccine*. 2018 Jun14;36(25):3701_3707 27_ Karlsson T, Cherif H. Mutations in the ENG, ACVRL1, and SMAD4 genes and clinical manifestations of hereditary haemorrhagic telangiectasia: experience from the Center for Osler's Disease, Uppsala University Hospital. *Ups J Med Sci*. 2018 Sep;123(3):153_157. 28_ Dickinson M, Cherif H, Fenaux P, Mittelman M, Verma A, Portella MSO, Burgess P, Ramos PM, Choi J, Platzbecker U. Azacitidine with or without eltrombopag for first_line treatment of intermediate_or high_risk MDS with thrombocytopenia. *Blood*. 2018 Oct 10. *Blood*_2018_06_855221. 29_ Ekstrand C, Linder M, Cherif H and Bahmanyar S; Patient characteristics when starting treatment and patterns of treatment in adults with chronic immune thrombocytopenia. *Blood Coagul Fibrinolysis*. 2019 Oct. 30_ Charlotta Ekstrand, Shahram Bahmanyar, Honar Cherif, Helle Kieler, Marie Linder; Cancer risk in patients with primary immune thrombocytopenia _ A Swedish nationwide register study; *Cancer Epidemiology*, 2020 Dec;69:101806. 31_ Christina Zhukovsky, Thomas Silfverberg, Andreas Tolf 1, Anne_Marie Landtblom, Honar Cherif, Kristina Carlson and Joachim Burman; Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing_remitting multiple sclerosis, *J Neurol Neurosurg Psychiatry*, 2021 Feb;92(2):189_194. 32_ Zjukovskaja Christina, Larsson Anders, Honar Cherif, Burman Joachim; Biomarkers of demyelination and axonal damage are decreased after autologous hematopoietic stem cell transplantation for multiple sclerosis, *Multiple Sclerosis and Related Disorders*, 2022 in press 33_ Thomas Silfverberg, Björn Wahlin, Kristina Carlson, Honar Cherif; Impact of COVID_19 on patients treated with autologous hematopoietic stem cell transplantation: A retrospective cohort study, *Ups J Med Sci*, 2022 Aug; 25:127

Projects

Member in the writing committee for guidelines available at Internet: Swedish National guidelines for the treatment of ITP (www.sfhem.se), Swedish National guidelines for the treatment of Thalassemia (www.sfhem.se), Swedish National guidelines for the treatment of TTP (www.sfhem.se) and Guideline for the management of hematological disorders for General Practitioners in Sweden (www.medibas.se)

Memberships

Committees and Administrative Service 2017_ date Member of the Regional Ethical Committee, Uppsala region 2016_ date Member of the Swedish National Reference Group for Antimycotics 2012_ 2015 Executive_board member, Swedish Hematology Association 2010_ 2020 Member, leading management group for the Dep. of Oncology, Hematology and Endocrine oncology, Uppsala University Hospital 2010_ 2020 Coordinator, unit for clinical researches, Dep. of Hematology, Uppsala University Hospital 2007_ 2009 Member, European Medical Expert Team in Infectious Diseases, Wyeth 2007_ 2009 Member, European Medical Expert Team in Oncology, Wyeth 2005_ 2008 Member, Infectious Diseases in Hematology Group, Hematologiskt Centrum, Karolinska University Hospital 2005_ 2008 Chairman, Benign Hematology Group, Hematologiskt Centrum, Karolinska University Hospital 2003+2004

Board Member, Reference Committee, Internal Medicine, Karolinska Institutet Memberships Swedish Hematology Association Swedish Oncology Association Swedish Medical Society European Hematology Association Fully registered member in the General Medical Council, UK

Other Relevant Information

Editorial reviewer Haematologica/ The Haematology Journal Leukemia and lymphoma Bone Marrow Transplantation Clinical Microbiology and Infection Journal of Antimicrobial Chemotherapy Supportive Care in Cancer Scandinavian Journal of Infectious Diseases Infection Yonsei Medical Journal Turkish Journal of Hematology Pediatric Hematology and Oncology Pediatric Transplantation Therapeutic Advances in Hematology Frontiers in Oncology Experience in clinical trials Investigator in studies mentioned above (see publication list). Principle investigator in ten different sponsored clinical trials and many academic clinical studies including National Investigator position in two of them. All within the fields of coagulation, myelodysplastic syndromes, chronic lymphocytic leukemia, acute myeloid leukemia, immune thrombocytopenias, vaccines and infectious complications in patients with hematological diseases.